Full-Time

Gestionnaire de cas sur le terrain

Bilingue, Bilingual Field Case Manager-Montreal

Posted on 11/7/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Montreal, QC, Canada

In Person

Some overnight travel within the assigned territory may be required.

Category
Medical, Clinical & Veterinary (2)
,
Requirements
  • IA or IAA; Inscription e0 l bertre de l3 ',' 'Ontario'; c'est inexact
Responsibilities
  • Customize program elements to meet the needs of assigned prescribing physicians.
  • Review patient status and assist the prescribing physician to complete patient enrolment, prepare payer forms to access public or private coverage by reviewing patient charts, documenting previous therapies and tests in order to complete the payer forms.
  • Identify obstacles to obtaining coverage and channel this information to the Program Manager.
  • Develop strong working relationships with physicians and physician office staff, providing additional office support to ensure smooth maintenance of patients enrolled in the program as needed.
  • Proactively provide assistance to resolve issues with regards to assigned physicians.
  • Provide training to physicians and clinics on program and new initiatives approved by the manufacturer.
  • Acts as a liaison and provide ongoing feedback to the Program Manager based on observations in the field and feedback from physicians as it pertains to quality of services, training, and other areas of importance.
  • Complete all relevant reports (program specific reports, expenses, etc.) as per specified timelines and as per required standards.
  • Welcome each patient to the program and capture required patient information; Provide reimbursement payer guidelines to patients and physicians; Ensure patient services are coordinated and tracked, according to KPIs, resulting in expedited access to therapy; Coordinate private and public coverage activity between patient, physician and insurers; Confirm outcome of reimbursement navigation with the patient; Provide information and navigate patient through financial assistance; Assist patient with pharmacy selection and coordinate drug delivery; Assist patient with coordination of therapy and ongoing therapy status; Refer the patient to contact their healthcare provider should the patient have clinical questions, assessments and situations that fall outside program provided materials or manufacturer product monograph; Report Adverse Events / Severe Adverse Events following program Standard Operating Procedures;
Desired Qualifications
  • Experience in case management is preferred; Minimum of three (3) years experience in a clinical setting is an asset; Travel within assigned territory; BCLS may be necessary depending on therapeutic area; Valid Drivers License, current auto insurance policy, and reliable transportation for regional travel; Experience and training in various therapeutic areas is an asset; Background in pharmaceutical business administration in sales and marketing is an asset; Knowledge of private and public reimbursement structures, systems and processes; Experience with reimbursement navigation, special authorization processes, appeals processes, and field-based reimbursement support and consultation; Strong analytical skills including interpretation of regulations and legislation; Fluency in French and English is required; Daily contacts with unilingual English-speaking customers, patients or peers from cross-functional teams; Bachelor s degree in health care or related discipline, or nurse diploma; Licensed Nurse (RN or RPN/LPN) with active registration; Case management experience preferred; Available to travel; Some overnight travel may be required; May be on standby/on call; The Field Case Manager will also be assigned other duties and tasks as required; Five years in healthcare, pharmaceutical or insurance industry or related experience; On standby/on call; Additional language assets; May require on-call.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty pharmaceuticals remain the main growth engine for higher-margin services.
  • Management targets $300 million in savings while sustaining about $3 billion free cash flow.
  • Share repurchases and accretive acquisitions can support earnings per share.

What critics are saying

  • Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
  • Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
  • Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and patient-support services.
  • It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
  • The company is expanding specialty care through OneOncology and EyeSouth retina assets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE